PTR 3046

Drug Profile

PTR 3046

Latest Information Update: 20 Jan 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peptor; Yissum Research Development Company
  • Class Cyclic peptides
  • Mechanism of Action Somatostatin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pancreatitis

Most Recent Events

  • 28 Sep 2002 Discontinued - Preclinical for Pancreatitis in Israel (unspecified route)
  • 28 Sep 2001 No-Development-Reported for Pancreatitis in Israel (Unknown route)
  • 17 Sep 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top